title: Plasma triglyceride determination can identify increased risk of statin-induced type 2 diabetes: a hypothesis.
abstract: OBJECTIVE
  To evaluate the ability of plasma triglyceride (TG) measurements to identify statin-treated persons at accentuated risk of statin-induced type 2 diabetes (T2DM).
  
  
  METHODS
  The experimental population consisted of nondiabetic, statin-treated patients (n = 469), classified as being at high risk for T2DM, subdivided on the basis of a plasma TG concentration of 1.7 mmol/L. Comparisons were made of demographic characteristics, concentrations of fasting glucose, insulin, HbA1c, and hs-CRP, oral glucose tolerance tests, estimates of insulin action and secretion, and lipid/lipoprotein profiles.
  
  
  RESULTS
  Despite similar fasting glucose and HbA1c concentrations, patients with elevated TG concentrations displayed markers of increased risk of T2DM (insulin resistance and compensatory hyperinsulinemia), more adverse lipid/lipoprotein profiles, and increased prevalence of abnormal hs-CRP values.
  
  
  CONCLUSIONS
  These findings demonstrate that plasma TG concentrations ≥ 1.7 mmol/L identified a subset of individuals at enhanced risk of developing statin-induced diabetes within a population classified prior to statin treatment as being at high risk of T2DM.
authors: Providence Little Company of Mary Cardiometabolic Center, Torrance, CA 90503, USA. Electronic address: Dr.armato@gmail.com.
authors: J
authors: J
authors: Armato
authors: Providence Little Company of Mary Cardiometabolic Center, Torrance, CA 90503, USA.
authors: R
authors: R
authors: Ruby
authors: Division of Cardiovascular Medicine Falk CVRC, Stanford Medical Center 300 Pasteur Drive Stanford, CA 94305, USA.
authors: G
authors: G
authors: Reaven
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000139:chemically induced*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008055:Lipids / Q000737:chemistry; D008074:Lipoproteins / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood*
chemical_list: D001786:Blood Glucose; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; D002097:C-Reactive Protein
keywords: Cardiovascular disease; Hyperinsulinemia; Insulin resistance; Statin-induced diabetes; Statins; Type 2 diabetes